stachydrine has been researched along with Diabetes Mellitus, Type 2 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abd El-Aty, AM; Cho, W; Hacimuftuoglu, A; Jeong, JH; Jung, TW; Kim, H; Lee, HJ; Oh, H; Park, SY | 1 |
| Chambers, ST; Dellow, WJ; Lever, M; Lunt, H; Robson, RA | 1 |
2 other study(ies) available for stachydrine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Stachydrine alleviates lipid-induced skeletal muscle insulin resistance via AMPK/HO-1-mediated suppression of inflammation and endoplasmic reticulum stress.
Topics: AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Endoplasmic Reticulum Stress; Glucose; Inflammation; Insulin; Insulin Resistance; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Palmitates; Proline; RNA; Tumor Necrosis Factor-alpha | 2022 |
Elevated glycine betaine excretion in diabetes mellitus patients is associated with proximal tubular dysfunction and hyperglycemia.
Topics: Adult; Aged; Aged, 80 and over; Alkaloids; Betaine; Biomarkers; Carnitine; Creatinine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Tubules, Proximal; Male; Middle Aged; Proline | 1999 |